AUS
NZ
UK
CA
USA
IND
Highlights:
- Commercial Partnership Secured: SkinBioTherapeutics to receive royalties on global sales of Croda’s products utilizing SkinBiotix technology.
- Innovative Cosmetics Platform: Extensive testing reveals enhanced benefits of SkinBiotix, elevating its appeal in the cosmetics industry.
- Strong Financial Outlook: The company forecasts positive cash flow by fiscal year 2025.
SkinBioTherapeutics PLC has finalized its agreement with Croda PLC, paving the way for the global commercial launch of its proprietary SkinBiotix technology. The collaboration ensures that SkinBioTherapeutics will earn royalties from worldwide sales of Croda’s products incorporating SkinBiotix, marking a transformative milestone for the AIM-listed biotech firm.
Enhanced Value Following Extensive Testing
Following extended trials, Croda identified additional benefits of SkinBiotix technology, strengthening its competitive edge in the cosmetics market. The results have bolstered confidence in the product’s potential, with Croda gearing up for a marketing launch at the prestigious In-Cosmetics Global exhibition scheduled for April 2025. This high-profile unveiling positions SkinBiotix for significant visibility among industry leaders and consumers.
Focus on Cosmetic Applications
The agreement allows SkinBioTherapeutics to retain rights to explore SkinBiotix applications beyond cosmetics while Croda exclusively focuses on cosmetic products. This strategic alignment enables both companies to leverage their expertise effectively, expanding the commercial potential of the technology across multiple sectors.
Path to Financial Strength
The partnership represents a significant financial boost for SkinBioTherapeutics, with management forecasting positive cash flow by fiscal year 2025. This optimism reflects the anticipated royalties from Croda’s sales and the broader market acceptance of SkinBiotix technology. The collaboration also reinforces SkinBioTherapeutics’ reputation as a pioneer in innovative skin health solutions, positioning the company for sustained growth.
Investor Confidence and Market Response
SkinBioTherapeutics shares rose 6% to 15.04p following the announcement, signaling strong market confidence in the agreement and the company’s growth trajectory. The successful commercial launch of SkinBiotix could serve as a catalyst for further partnerships and market expansion, solidifying SkinBioTherapeutics' position as a leader in skin health innovation.
The partnership between SkinBioTherapeutics and Croda marks a pivotal step in bringing cutting-edge biotech solutions to the cosmetics industry while strengthening the company’s financial foundation for long-term success.
